๐บ๐ธ#bonds #monetarypolicy #macro
first time in 30 years - ัorporate bond yields are below the Fed funds rate
first time in 30 years - ัorporate bond yields are below the Fed funds rate
โก๏ธ๐บ๐ธ#TEVA #report #watchlist
Teva Pharmaceutical:
- Q4 Non-GAAP EPS of $0.71 in-line
- Revenue of $3.9B (-4.9% Y/Y) misses by $10M
2023 business outlook: Revenues are expected to be $14.8 - $15.4 billion vs. consensus of $15.19B; Adjusted EBITDA of $4.5 - $4.9 billion; Non-GAAP diluted EPS is expected to be $2.25 - $2.55 vs. consensus of $2.52; Free cash flow is expected to be $1.7 - $2.1 billion.
Teva Pharmaceutical:
- Q4 Non-GAAP EPS of $0.71 in-line
- Revenue of $3.9B (-4.9% Y/Y) misses by $10M
2023 business outlook: Revenues are expected to be $14.8 - $15.4 billion vs. consensus of $15.19B; Adjusted EBITDA of $4.5 - $4.9 billion; Non-GAAP diluted EPS is expected to be $2.25 - $2.55 vs. consensus of $2.52; Free cash flow is expected to be $1.7 - $2.1 billion.
โ ๏ธ๐บ๐ธ#inversion #us #bonds #markets
BBG: US bonds โ 2-10 Yield Curve Inversion continues to intensify = the longest and deepest in 40 years
* yield curve inversions (or negative yield curve) = itโs one signal of a future recession โ details
BBG: US bonds โ 2-10 Yield Curve Inversion continues to intensify = the longest and deepest in 40 years
* yield curve inversions (or negative yield curve) = itโs one signal of a future recession โ details
๐บ๐ธ#EQC #report #watchlist
Equity Commonwealth:
- Q4 FFO of $0.21
- Revenue of $15.79M (+9.7% Y/Y)
Equity Commonwealth:
- Q4 FFO of $0.21
- Revenue of $15.79M (+9.7% Y/Y)
๐บ๐ธ#NLY #report #watchlist
Annaly Capital Management:
- Q4 Non-GAAP EPS of $0.89 beats by $0.01
- Q4 GAAP EPS -$1.96 per average common share
- FY2022 EPS $3.93 per average common share
#dividends declared dividend of $0.88 per share
Annaly Capital Management:
- Q4 Non-GAAP EPS of $0.89 beats by $0.01
- Q4 GAAP EPS -$1.96 per average common share
- FY2022 EPS $3.93 per average common share
#dividends declared dividend of $0.88 per share
๐บ๐ธ#CXW #report #watchlist
Corecivic:
- Q4 FFO of $0.42 beats by $0.09
- Revenue of $471.43M (-0.1% Y/Y)
2023 Outlook: Net income $58.0 million to $75.0 million, FFO per diluted share $1.35 to $1.50, Diluted EPS $0.50 to $0.65, EBITDA $298.5 million to $313.5 million, during 2023, expect to invest $64.0 million to $67.0 million in CAPEX
Corecivic:
- Q4 FFO of $0.42 beats by $0.09
- Revenue of $471.43M (-0.1% Y/Y)
2023 Outlook: Net income $58.0 million to $75.0 million, FFO per diluted share $1.35 to $1.50, Diluted EPS $0.50 to $0.65, EBITDA $298.5 million to $313.5 million, during 2023, expect to invest $64.0 million to $67.0 million in CAPEX
โ ๏ธ๐#markets #sentiment #warning
Morgan: investor risk appetite in global markets = extremely high values
Morgan: investor risk appetite in global markets = extremely high values